Remarkably, the current study demonstrated that IL-2/IL-2Ab treatment of Tregs suppressed the detrimental inflammatory response associated with cell death, supporting the application of Tregs in conjunction with IL- IL-2/IL-2R to curtail secondary cell death after stroke. This evidence concerns the gene IL2RA and stroke disorder.